• +1-646-491-9876
    • +91-20-67278686

    Search

    Sinusitis - Pipeline Review, H1 2017

    Sinusitis - Pipeline Review, H1 2017

    • Report Code ID: RW0001767492
    • Category Pharmaceuticals
    • No. of Pages 95
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Sinusitis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis - Pipeline Review, H1 2017, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.

    Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Sinusitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 3, 5 and 2 respectively.

    Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis (Ear Nose Throat Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Sinusitis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Sinusitis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Sinusitis (Ear Nose Throat Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Sinusitis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Sinusitis - Overview
    Sinusitis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Sinusitis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Sinusitis - Companies Involved in Therapeutics Development
    AmpliPhi Biosciences Corp
    F. Hoffmann-La Roche Ltd
    Knopp Biosciences LLC
    Kyorin Pharmaceutical Co Ltd
    Kyowa Hakko Kirin Co Ltd
    Merck & Co Inc
    OptiNose US Inc
    Pfizer Inc
    Quorum Innovations LLC
    Regeneron Pharmaceuticals Inc
    Therabron Therapeutics Inc
    Sinusitis - Drug Profiles
    ABPA-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ABSA-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    benralizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CG-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dexpramipexole dihydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dupilumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fluticasone propionate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GM-0111 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lascufloxacin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    omalizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    P-008 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PCL-1550 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-06817024 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Qi-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RG-6149 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Sinusitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Chronic Rhinosinusitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    solithromycin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Sinusitis - Dormant Projects
    Sinusitis - Product Development Milestones
    Featured News & Press Releases
    Mar 07, 2017: Knopp Biosciences Announces Publication of Eosinophil-Lowering Effects of Dexpramipexole in Multiple Clinical Trials
    Dec 19, 2016: AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients
    Oct 25, 2016: AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis
    Sep 20, 2016: AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients
    Sep 16, 2016: OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhinosinusitis with and without Nasal Polyps
    Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress
    Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus
    Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort
    Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab
    Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association
    Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01
    Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections
    Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
    Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Sinusitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Sinusitis - Pipeline by AmpliPhi Biosciences Corp, H1 2017
    Sinusitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Sinusitis - Pipeline by Knopp Biosciences LLC, H1 2017
    Sinusitis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
    Sinusitis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
    Sinusitis - Pipeline by Merck & Co Inc, H1 2017
    Sinusitis - Pipeline by OptiNose US Inc, H1 2017
    Sinusitis - Pipeline by Pfizer Inc, H1 2017
    Sinusitis - Pipeline by Quorum Innovations LLC, H1 2017
    Sinusitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Sinusitis - Pipeline by Therabron Therapeutics Inc, H1 2017
    Sinusitis - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Sinusitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AmpliPhi Biosciences Corp
    F. Hoffmann-La Roche Ltd
    Knopp Biosciences LLC
    Kyorin Pharmaceutical Co Ltd
    Kyowa Hakko Kirin Co Ltd
    Merck & Co Inc
    OptiNose US Inc
    Pfizer Inc
    Quorum Innovations LLC
    Regeneron Pharmaceuticals Inc
    Therabron Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//sinusitis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//sinusitis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//sinusitis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments